Breaking New Ground in Cervical Metastatic Carcinoma of Unknown Primary: Neoadjuvant Immunochemotherapy's Pathologic Regression and Survival Advantage
1. 系统已在2026-04-02 15:22:40对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
Q Jin, X Zhang, J Yuan, Q Fang, W Du
Annals of Surgical Oncology, 2026
Springer
Background Cervical metastatic carcinoma of unknown primary (CMCUP) poses significant therapeutic challenges because of its aggressive biology and the absence of standardized treatment protocols. While neoadjuvant immunochemotherapy (NICT) has demonstrated efficacy across various malignancies, its application in CMCUP remains poorly characterized. Methods This retrospective cohort study evaluated 98 consecutive patients with CMCUP treated at a tertiary cancer center between 2015 and 2024. Patients were …
